{"entity":{"id":"nct07299747","kind":"trial","name":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of VBC103 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","summary":"Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07299747 by VelaVigo Bio Inc, with 255 participants planned, started 2025-12-04 and due to reach its primary completion in 2027-12-01. Interventions recorded: VBC103.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07299747","url":"https://clinicaltrials.gov/study/NCT07299747"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc"],"targets":["trop2","nectin4"],"drugs":[],"companies":["velavigo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07299747","phase":"1/2","setting":"A Phase I/IIa Clinical Study Evaluating the Bispecific Antibody-Drug Conjugate VBC103 Targeting Nectin-4 and TROP2 in Subjects With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","started":"2025-12-04","startedType":"actual","enrolled":255,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07299747/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"velavigo","kind":"company","name":"VelaVigo","route":"/companies/velavigo/"}]}}